Skip to Main
Formerly Digestome Therapeutics

Viage Therapeutics (Viage), a neuroscience company based on a platform of novel neurotherapeutics, today announced positive findings from its Phase 1 study of DGX-001, a first-in class oral therapeutic targeting the AVPR1A receptor in the gut. DGX-001 demonstrated both a favorable safety profile and proof of concept data relating to its mechanism of action (MoA), which modulates the vagus nerve via specific receptor interactions on enteroendocrine cells in the gut, with no systemic exposure of the drug and no need to penetrate the blood brain barrier.